The following is a summary of the Knight Therapeutics Inc. (KHTRF) Q3 2024 Earnings Call Transcript:

Financial Performance:

• Q3 revenue reached $91 million, a 12% increase year-over-year, with a constant currency basis increase of 18%.

• Adjusted EBITDA was $13.5 million, down 13% from the previous year, with adjusted EBITDA per share at $0.13, a decrease of 10%.

• Gross margin was reported at 47%, down from 52% the previous year, primarily due to product mix, including a higher proportion of AmBisome sales to the Ministry of Health.

• Operating expenses excluding amortization of non-current assets increased by 11% to $30.5 million, driven by marketing spends for new product launches and increases in R&D and G&A costs.

Business Progress:

• Launched NCIB, purchasing 437,500 common shares at an average price of $5.65.

• Advanced the pipeline with regulatory approval of Minjuvi in Mexico, expecting launch in first half of 2025.

• Delivered record nine-month revenues of over $271 million and adjusted EBITDA of over $42 million, driven by promoted portfolio growth and recent product launches in Canada and Brazil.

Opportunities:

• Continue to drive growth through Knight's innovative promoted portfolio, including recent launches and expected regulatory approvals, targeting a combined potential revenue of over $150 million.

Risks:

• Market and currency fluctuations impacting revenue growth and profitability, particularly noted in currency depreciation from Q1 to Q3 2024 affecting LatAm financial results.

• Potential generic entry for Lenvima leading to a gradual revenue decline over several years.

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.